Opioid overdose and inpatient care for substance use disorder care in Massachusetts.


Journal

Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909

Informations de publication

Date de publication:
05 2020
Historique:
received: 09 08 2019
revised: 27 01 2020
accepted: 28 01 2020
entrez: 23 3 2020
pubmed: 23 3 2020
medline: 29 7 2021
Statut: ppublish

Résumé

Inpatient treatment for substance use disorders is a collection of strategies ranging from short term detoxification to longer term residential treatment. How those with opioid use disorder (OUD) navigate this inpatient treatment system after an encounter for detoxification and subsequent risk of opioid-related overdose is not well understood. We used a comprehensive Massachusetts database to characterize the movement of people with OUD through inpatient care from 2013 to 2015, identifying admissions to inpatient detoxification, subsequent inpatient care, and opioid overdose while navigating treatment. We measured the person-years accumulated during each transition period to calculate rates of opioid-related overdose, and investigated how overdose differed in select populations. Sixty-one percent of inpatient detoxification admissions resulted in a subsequent inpatient detoxification admission without progressing to further inpatient care. Overall, there were 287 fatal and 7337 non-fatal overdoses. Persons exiting treatment after detoxification had the greatest risk of overdose (17.3 per 100 person-years) compared to those who exited after subsequent inpatient care (ranging from 5.9 to 6.6 overdoses per 100 person-years). Non-Hispanic whites were most at risk for opioid related overdose with 16 overdoses per 100 person-years and non-Hispanic blacks had the lowest risk with 5 overdoses per 100 person-years. The majority of inpatient detoxification admissions do not progress to further inpatient care. Recurrent inpatient detoxification admission is common, likely signifying relapse. Rather than functioning as the first step to inpatient care, inpatient detoxification might be more effective as a venue for implementing strategies to expand addiction services or treatment such as medications for opioid use disorder.

Sections du résumé

BACKGROUND
Inpatient treatment for substance use disorders is a collection of strategies ranging from short term detoxification to longer term residential treatment. How those with opioid use disorder (OUD) navigate this inpatient treatment system after an encounter for detoxification and subsequent risk of opioid-related overdose is not well understood.
METHODS
We used a comprehensive Massachusetts database to characterize the movement of people with OUD through inpatient care from 2013 to 2015, identifying admissions to inpatient detoxification, subsequent inpatient care, and opioid overdose while navigating treatment. We measured the person-years accumulated during each transition period to calculate rates of opioid-related overdose, and investigated how overdose differed in select populations.
RESULTS
Sixty-one percent of inpatient detoxification admissions resulted in a subsequent inpatient detoxification admission without progressing to further inpatient care. Overall, there were 287 fatal and 7337 non-fatal overdoses. Persons exiting treatment after detoxification had the greatest risk of overdose (17.3 per 100 person-years) compared to those who exited after subsequent inpatient care (ranging from 5.9 to 6.6 overdoses per 100 person-years). Non-Hispanic whites were most at risk for opioid related overdose with 16 overdoses per 100 person-years and non-Hispanic blacks had the lowest risk with 5 overdoses per 100 person-years.
CONCLUSIONS
The majority of inpatient detoxification admissions do not progress to further inpatient care. Recurrent inpatient detoxification admission is common, likely signifying relapse. Rather than functioning as the first step to inpatient care, inpatient detoxification might be more effective as a venue for implementing strategies to expand addiction services or treatment such as medications for opioid use disorder.

Identifiants

pubmed: 32199545
pii: S0740-5472(19)30445-3
doi: 10.1016/j.jsat.2020.01.017
pmc: PMC7928069
mid: NIHMS1568186
pii:
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-48

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046527
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Drug Alcohol Depend. 2019 Aug 1;201:227-235
pubmed: 31254749
Drug Alcohol Depend. 2007 Jul 10;89(2-3):161-9
pubmed: 17280803
J Subst Abuse Treat. 2014 Aug;47(2):130-9
pubmed: 24912862
J Addict Med. 2018 Jan/Feb;12(1):19-23
pubmed: 28885299
Drug Alcohol Depend. 2010 Apr 1;108(1-2):65-9
pubmed: 20022184
J Subst Abuse Treat. 2015 Dec;59:99-103
pubmed: 26254317
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
Int J Drug Policy. 2017 Jan;39:114-120
pubmed: 27907848
J Subst Abuse Treat. 2017 Nov;82:113-121
pubmed: 29021109
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Drug Alcohol Depend. 2019 Jul 1;200:34-39
pubmed: 31082666
Addiction. 2016 Feb;111(2):298-308
pubmed: 26452239
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
JAMA. 2000 Oct 4;284(13):1689-95
pubmed: 11015800
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD003409
pubmed: 23450540
J Subst Abuse Treat. 2006 Mar;30(2):121-8
pubmed: 16490675
JAMA. 2015 Oct 13;314(14):1515-7
pubmed: 26462001
J Subst Abuse Treat. 2018 Feb;85:90-96
pubmed: 28733097
J Subst Abuse Treat. 2006 Dec;31(4):439-45
pubmed: 17084799
Addiction. 2007 Dec;102(12):1954-9
pubmed: 18031430
Subst Abus. 2016 Apr-Jun;37(2):364-71
pubmed: 26308604
Drug Alcohol Depend. 2018 Feb 1;183:192-200
pubmed: 29288914

Auteurs

Jake R Morgan (JR)

Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, MA, USA. Electronic address: jakem@bu.edu.

Jianing Wang (J)

Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA.

Joshua A Barocas (JA)

Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA, USA; Brigham and Women's Hospital, Division of Infectious Diseases, Boston, MA, USA.

Jenifer L Jaeger (JL)

Boston Public Health Commission, Boston, MA, USA.

Natalie N Durham (NN)

Massachusettes Department of Public Health, Boston, MA, USA.

Hermik Babakhanlou-Chase (H)

Massachusettes Department of Public Health, Boston, MA, USA.

Monica Bharel (M)

Massachusettes Department of Public Health, Boston, MA, USA.

Alexander Y Walley (AY)

Massachusettes Department of Public Health, Boston, MA, USA; Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Boston, MA, USA.

Benjamin P Linas (BP)

Department of Medicine, Section of Infectious Diseases, Boston Medical Center, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH